ライフサイエンスコーパス: antibody test

1 HCV RNA with the use of a more sensitive HCV-antibody test).

2 infection during the epidemic (positive IgM antibody tests).

3 t year, and 1861 did not provide samples for antibody testing).

4 gainst endomysium (P>.05 vs controls for all antibodies tested).

5 s demonstrate a success rate of 82% (100/122 antibodies tested).

6 tibody (HCV AB) using the OraQuick HCV Rapid Antibody Test.

7 cted erythrocytes in an indirect fluorescent antibody test.

8 oronavirus (BCV), on an indirect fluorescent antibody test.

9 ssay to the gold standard direct fluorescent-antibody test.

10 RNA test done within 6 months of a positive antibody test.

11 aving an RNA test after a first positive HCV antibody test.

12 included gastrointestinal symptoms or serum antibody tests.

13 untary HIV counseling and testing by 2 rapid antibody tests.

14 50 had sera previously referred for selected antibody tests.

15 ripheral blood samples were obtained for HIV antibody testing.

16 to 47 months (mean = 26.1 months) before JCV antibody testing.

17 erum antitransglutaminase and antiendomysial antibody testing.

18 he newborn for rubella immunoglobulin (Ig) M antibody testing.

19 hHepc knock-in mice were produced to enable antibody testing.

20 anti-cyclic citrullinated peptide (anti-CCP) antibody testing.

21 al risk stratification, and state-of-the-art antibody testing.

22 c to B. burgdorferi, by indirect fluorescent antibody testing.

23 oximately 10% compared with conventional HIV antibody testing.

24 HSV-2 and T. pallidum were detected by serum antibody testing.

25 The primary objective was safety, including antibody testing.

26 or subsequent use in vaccine and therapeutic antibody testing.

27 cterise the antigen and develop an assay for antibody testing.

28 diagnosis depends on sensitive and specific antibody testing.

29 tein was not detected with either of the two antibodies tested.

30 concentration values for the three anti-CD4 antibodies tested.

31 n fact, it was not neutralized by any of the antibodies tested.

32 on geniculocortical axons for all five TrkB antibodies tested.

33 ars to play only a limited role in the three antibodies tested.

34 f the four different monoclonal anti-V3 loop antibodies tested.

35 With antibody testing, 0.2% of patients (2 of 1044) developed

36 th nonspecific bands of approximately 20% of antibodies tested (5/25).

37 T-Def eight [11%] of 75; p<0.0001) and rapid antibody test (54 [53%] of 101 vs eight [11%] of 74; p<0

38 e directly compared central findings from 16 antibody tests (8 for TGA-IgA, 1 for TGA-IgG, 6 for IgG

39 osis of AHR compared with the donor-specific antibody test (90%).

40 re calculated to estimate the performance of antibody tests against tissue transglutaminase (TG2), de

41 Therefore, we suggest that the HCV antibody testing algorithm for the VITROS assay might be

42 m) as well as 1 algorithm that relies on HIV antibody testing alone (Antibody algorithm).

43 ned to be H. pylori positive by histology or antibody testing alone.

44 The two antibodies tested and the expressed scFv all efficiently

45 n of Bax and p53 was found regardless of the antibodies tested and was specific since Bcl-xL/p53 comp

46 NA gene fragments by an indirect fluorescent antibody test and a nested PCR assay, respectively.

47 CV infection was assessed via a positive HCV antibody test and a positive HCV RNA test.

48 e positive for E. canis by immunofluorescent antibody test and in various phases of acute or chronic

49 Bordetella culture and/or direct fluorescent antibody testing and a second LightCycler PCR assay (tar

50 e for P/Q-type voltage-gated calcium channel antibody testing and all seven were positive.

51 ldren to support diagnostic decisions, drive antibody testing and generate disease mechanism hypothes

52 undiagnosed HCV disease, as suggested by HCV antibody testing and HCV polymerase chain reaction and c

53 t were assayed by indirect immunofluorescent antibody testing and immunoprecipitation for reactivity

54 action (MLR), cell-mediated lysis (CML), and antibody testing and in vivo by kidney transplantation.

55 tive living organ donors, and to conduct HIV antibody testing and NAT as close to the time of donatio

56 r autoimmune encephalitis are too reliant on antibody testing and response to immunotherapy, which mi

57 ths), saliva was collected for anonymous HCV antibody testing and risk behavior data were obtained th

58 HCV is used to confirm a positive result on antibody testing and to provide prognostic information f

59 Clinicians should consider antibody testing and vaccination for this vulnerable pop

60 Indirect fluorescence antibody tests and enzyme-linked immunosorbent assays ma

61 demographic information and performed serial antibody tests and follow-up evaluations.

62 IV) infection cannot be diagnosed by routine antibody tests and is rarely diagnosed in clinical pract

63 seroconversion rates of 86%-96% by other VZV antibody tests and suggest that many cases of varicella

64 justed risk ratio (aRR) for receiving an HCV antibody test, and costs were estimated using activity-b

65 -antibody combination, HIV-1 and HIV-2 rapid antibody test, and quantitative anti-gp120 IgG ELISA.

66 plement fixation test, the immunofluorescent antibody test, and Western blot analysis.

67 ative to control was reduced at all doses of antibody tested, and the magnitude of growth inhibition

68 r DNA amplification test, direct fluorescent antibody testing, and a DNA amplification test to detect

69 aracteristics, OMG symptoms, results of AChR antibody testing, and progression time to generalized my

70 at ATG produces positive results in anti-HLA antibody testing, and treatment to remove ATG abolishes

71 itis A, 659 (12.4%) had negative hepatitis A antibody tests, and 1671 (31.4%) had no testing or vacci

72 titis A, 122 (7.5%) had negative hepatitis A antibody tests, and 535 (32.7%) had no testing or vaccin

73 results of heparin-induced platelet factor 4 antibody tests, and outcomes.

74 Among several anti-FVIII antibodies tested (anti-C1 (GMA8011), anti-C2 (ESH4 and

75 Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant hi

76 A 2-tiered antibody testing approach is recommended, but single-tie

77 atients, but clinical features and anti-GQ1b antibody testing are diagnostically more informative.

78 lts should be limited to situations in which antibody tests are known to be insufficient.

79 y-determining regions (CDRs) from monoclonal antibodies tested as synthetic peptides display anti-inf

80 cardiolipin, and anti-beta(2)-glycoprotein I antibody tests at baseline had positive results at 24 we

81 Adding HIV and HCV viral RNA testing to antibody testing averts 14.8-30.3 HIV and 3.7-7.7 HCV in

82 As antibody testing becomes more widely available, and many

83 l three neutralizing, LF-specific monoclonal antibodies tested bound specific peptide sequences that

84 e synergy with all tumor-specific monoclonal antibodies tested by increasing phagocytosis in vitro an

85 We tested the accuracy of the JCV serum antibody test by comparing the results of JCV serology t

86 IgA antibeta 2 Glycoprotein I (beta2GPI) antibodies test can identify some patients with antiphos

87 HIV antibody tests cannot be used to reconfirm HIV diagnosis

88 sting the original specimens with a blocking antibody test (Chlamydiazyme), a cytospin DFA (MicroTrak

89 ack of standardized methods for anti-retinal antibody testing continues to challenge the interpretati

90 Multiplex P. falciparum antibody testing could provide estimates of long-term an

91 etions were sent to central laboratories for antibody testing, culture, DNA testing, and histopatholo

92 Complement-dependent cytotoxic antibody testing demonstrated that none of the sheep imp

93 had been characterized by direct fluorescent antibody test (DFA) and DNA sequencing analysis were tes

94 cytospin-enhanced direct immunofluorescence antibody testing (DFA) and real-time reverse transcripta

95 e performance of culture, direct fluorescent-antibody testing (DFA), and an in-house-developed PCR te

96 citation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and costs for each of the i

97 profile (Sabin-Feldman dye test, IgA and IgE antibody tests, differential agglutination [AC/HS] test,

98 consecutively submitted for West Nile virus antibody testing during 2 days of the 2003 West Nile vir

99 er recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >4 SD from the no

100 ed PCR-based and enzyme-linked immunosorbent antibody test (ELISA) protocols.

101 In general, however, antibody tests, especially DPG-IgA, are of limited value

102 the sensitivity of the standard fluorescent-antibody test (FAT) for rabies antigen and that of hnRT-

103 d for CDV antigen using a direct fluorescent antibody test (FAT).

104 al diagnosis of dermatitis herpetiformis and antibody test findings against aquaporin-4 were positive

105 Screening with the HCV antibody test followed by the nucleic acid test for conf

106 rgy (LAA) by questionnaires and specific-IgE antibody test for 555 rodents and/or rabbit handlers fro

107 stochemistry, suggesting a simple diagnostic antibody test for EDMD families.

108 d negative results by the direct fluorescent antibody test for respiratory syncytial virus, influenza

109 To develop a rapid antibody test for Sin Nombre hantavirus (SNV) infection

110 fever and a positive rapid immunoglobulin M antibody test for typhoid (TUBEX TF); a confirmed case r

111 A rapid HIV-1 antibody test for whole blood was used.

112 Natalizumab, the first anti-integrin antibody tested for treatment of IBD, blocks the alpha4

113 Given that antibody testing for HEV infection is not routinely obta

114 Current antibody testing for human granulocytic ehrlichiosis rel

115 atients with acute viral hepatitis underwent antibody testing for other causes of liver disease and s

116 ere tested by culture and direct fluorescent antibody testing for respiratory syncytial virus (RSV),

117 New antibody tests for antiphospholipid antibody syndrome ar

118 Antibody tests for dpgli yielded superior results compar

119 Routine antinuclear antibody testing, for example, is not recommended withou

120 ood samples were available for anti-JC virus antibody testing from 5896 patients with multiple sclero

121 ndii infection (a positive anti-T gondii IgM antibody test) from Erechim, Rio Grande do Sul state, Br

122 siblings who did not undergo postvaccination antibody tests (group 2) were studied.

123 assay antigen detection method, and a rapid antibody test had 89 to 100% sensitivity and 89 to 95% s

124 an two-thirds of persons with a positive HCV antibody test had a follow-up RNA test.

125 The anti-rTC antibody test had a sensitivity of 0.50 and a specificit

126 Routine antinuclear antibody testing has a low positive predictive value for

127 Direct fluorescent-antibody testing has a specificity of 99.6% but a sensit

128 Anti-GQ1b antibody testing has allowed clinicians to develop a gre

129 However, as availability of antibody testing has increased, the range of associated

130 canis antigens by indirect immunofluorescent antibody testing have been attributed to infection with

131 Urine-based antibody tests have also indicated a compartmentalized a

132 Since herpes simplex virus type 2 (HSV-2) antibody tests have become commercially available, an in

133 ning studies that use sensitive and specific antibody tests have revealed the disease to be common, o

134 Current HHV-8 antibody tests have uncertain accuracy in asymptomatic H

135 Accordingly, the antibodies tested here stained cytoplasmic TRAP brightly

136 d the diagnostic performance of standard HIV antibody tests (i.e., enzyme immunoassay and Western blo

137 Discordant rapid antibody tests identified 7 of 21 (33.3% sensitivity), s

138 ene (16S) PCR and indirect immunofluorescent antibody test (IFA) were retrospectively tested with the

139 KLC-All was unique among antibodies tested in releasing kinesin from purified mem

140 y paediatric neurology centres to Oxford for antibody testing in 2007-2010.

141 ce of H. pylori was determined by biopsy and antibody testing in 84 patients.

142 the positive predictive value of antinuclear antibody testing in diagnosing SLE in a patient with uve

143 limitations, and explores the utility of HLA antibody testing in identifying and managing important p

144 elf-administered questionnaires and oral HIV antibody testing in MSM recruited in gay social venues i

145 determine the sensitivity and specificity of antibody testing in paired serum and CSF samples.

146 sensitivity and specificity of serum and CSF antibody testing in patients with anti-NMDA receptor enc

147 o establish the value of routine antinuclear antibody testing in patients with uveitis.

148 (b) the interpretation of pretransplantation antibody testing in the context of various clinical sett

149 enge that was resolved through rapid typhoid antibody testing in the field and subsequent blood cultu

150 and islet cells), and (c) the application of antibody testing in the posttransplantation setting.

151 is study aimed to compare the performance of antibody tests in predicting small-intestinal mucosal st

152 A combination of three or four antibody tests including IgA anti-tissue transglutaminas

153 hology, molecular technologies and sensitive antibody testing into one enhanced diagnostic system.

154 Accordingly, the JCV serological antibody test is of paramount importance in determining

155 nucleic acid test (NAT) for HCV RNA when the antibody test is positive, are compared.

156 interference when the indirect fluorescence antibody test is used to detect fluorescence of morulae

157 Antigliadin antibody testing is essential at first presentation of p

158 The sensitivity of NMDA receptor antibody testing is higher in CSF than in serum.

159 Antibody testing is often useful for the identification

160 of brain natriuretic peptide, and leukocyte antibody testing is the best strategy currently availabl

161 sensitivity of acetylcholine receptor (AChR) antibody testing is thought to be lower in ocular myasth

162 One-time antibody test of 1945-1965 birth cohort.

163 HIV-1 antibody testing of OMT samples is a highly accurate alt

164 anced surveillance of measles, including IgM antibody testing of oral fluid from clinically diagnosed

165 Indirect immunofluorescent antibody testing of serum from 57 blood donors implicate

166 Immunoglobulin M antibody testing of serum specimens and cerebrospinal fl

167 By second-generation antibody testing of stored serum samples, 142 participan

168 From 2003-2010, 5860 persons had a positive antibody test, of whom 3570 (60.9%) had a follow-up RNA

169 The indirect fluorescence antinuclear antibody test on Hep-2 cells demonstrated antinuclear ti

170 blic clinics employed the OraQuick HCV rapid antibody test on site, and all results were verified by

171 for rhesus monkeys on the basis of sensitive antibody tests only.

172 Of the anti-syntaxin antibodies tested, only anti-syntaxin 2 antibody inhibit

173 showed that: (i) of the purified or elicited antibodies tested, only antibodies against the N-termina

174 that tested positive in a direct fluorescent-antibody test or in a confirmatory PCR test for an alter

175 or cell lysates was revealed by fluorescent antibody testing or enzyme-linked immunosorbent assay, r

176 ting with the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test (OraSure Technologies, Bethlehem, Pennsylv

177 Patients who had only direct fluorescent antibody testing performed or concurrent viral infection

178 Unlike several Epac-specific antibodies tested, Phi-O-Me-cAMP exhibited dramatically

179 ot fully understood, but it is believed that antibodies testing positive in the serotonin release ass

180 dies to intact platelets and found that most antibodies testing positive in the SRA, but none of thos

181 s were detected in 63 of 63 horses with EIAV antibody test-positive histories on approved serologic t

182 Advances in the efficacy of serological antibody testing potentiate the possibility of future ac

183 The panel reactive antibody test (PRA) is an established method for assessi

184 ics switched from a direct immunofluorescent antibody testing procedure to an enzyme immunoassay with

185 Combining antigen and EIA antibody testing provides an optimal method for diagnosi

186 All patients underwent HLA-antibody testing quarterly pretransplant and at regular

187 g to determine whether the results of an IgM antibody test reflect the likelihood of a recently acqui

188 o submitted convalescent serum specimens for antibody testing, respiratory tract virus infections wer

189 Women were less likely to have a positive antibody test result (OR, 0.36; 95% CI, 0.19-0.68; P = .

190 ts and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not av

191 ts and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not av

192 ion assay or indirect fluorescent treponemal antibody test result), compared with 3 (1%) of 233 uninf

193 pt hyperplasia and a positive antiendomysial antibody test result.

194 ere significantly associated with a positive antibody test result.

195 Antinuclear antibodies test results were negative.

196 , 1.4% to 17.5%) had positive antiendomysial antibody test results and small-bowel biopsy specimens c

197 e the probability of seropositivity prior to antibody test results.

198 ormed on subjects regardless of symptoms, or antibody test results.

199 were significantly associated with positive antibody test results.

200 Among the 223 participants, AChR antibody testing results were positive in 158 participan

201 Antibody testing revealed a high prevalence for at least

202 ecificity remain undetermined, cerebrospinal antibody testing should also be performed.

203 Antigen/antibody tests should be preferred to avoid missing case

204 All of eight anti-tau antibodies tested showed dephosphorylation at 0 h and hy

205 d PHA-L--labeled afferents, 3 of 5 anti-TrkB antibodies tested showed significant colocalization with

206 Indirect immunofluorescent antibody testing showed that the patient's serum had str

207 observations, CD4-Ig, but none of the CD4bs antibodies tested, substantially increased HIV-1 infecti

208 Rapid human immunodeficiency virus (HIV) antibody tests support the effort to expand access to HI

209 computerized algorithm, termed the Kentucky Antibody Testing System (KATS), that predicts class I HL

210 15 were randomly selected for infection and antibody testing: TF and TT were assessed, conjunctival

211 ntly higher positive rate for anti-mouse IgE antibody test than the other (38.1% vs 8.8%, p<0.01) .

212 We demonstrate a higher sensitivity of AChR antibody testing than previously reported in the largest

213 ntains epitopes for all monoclonal and human antibodies tested to date.

214 Glycoprotein G is currently the target of an antibody test to differentiate HSV-1 from HSV-2; however

215 of the average time from the first positive antibody test to the diagnosis are underestimates of the

216 atients referred on clinical grounds for RNP antibody testing to a reference laboratory between 1989

217 Physicians must perform HIV antibody testing to determine which persons are already

218 Because HSV glycoproteins are the focus of antibody tests to detect and differentiate between infec

219 immunodeficiency virus (HIV) to standard HIV antibody tests to detect persons with acute HIV infectio

220 was to compare celiac disease (CD)- specific antibody tests to determine if they could replace jejuna

221 received both HBsAg and hepatitis B surface antibody tests to determine prior exposure and susceptib

222 ich may account for the failure of sensitive antibody tests to distinguish HSV-1 from HSV-2 in some A

223 l HIVST kits (OraQuick ADVANCE Rapid HIV-1/2 Antibody Test) to adult (>/=16 y old) residents (n = 16,

224 The symposium focused on antibody testing, transplantation pathology, molecular d

225 However, antibody testing using cells expressing voltage-gated po

226 Assessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fingerpr

227 No elimination of antiviral antibodies tested was seen.

228 en into account, the sensitivity of standard antibody testing was 0.962 (95 percent confidence interv

229 tive predictive value of routine antinuclear antibody testing was 2.9% (95% CI, 2.65%-3.19%).

230 Non-HLA antibody testing was included in the posttransplant eval

231 cal serotype-specific immunoglobulin G (IgG) antibody testing was offered as a clinical service to al

232 Ehrlichia antibody testing was performed by using an indirect immu

233 Anti-HCV antibody testing was performed for 4582, or 90%, of all

234 HAV antibody testing was performed in 640 subjects (53.6%),

235 boratory, autoantibody, and antiphospholipid antibody testing was performed in the hospitals' clinica

236 HCV antibody testing was performed on excess samples.

237 Anti-Porphyromonas gingivalis antibody testing was performed to assess prior exposure

238 Antiendomysial antibody testing was used to screen for celiac disease.

239 Several of the antibodies tested were found to bind to regions already

240 ewhat surprising, the majority of commercial antibodies tested were unable to specifically recognize

241 IgA endomysial antibodies tests were associated with high specificity.

242 ow aspiration, Coombs test, and antiplatelet antibody test were negative.

243 Specimens for solid-phase HLA antibody testing were available in 199 patients.

244 xposures and blood samples for H5N1-specific antibody testing were collected.

245 tion studies, and indirect immunofluorescent antibody testing were used to confirm the presence of Ba

246 ed persistently seronegative (HIPS) on HIV-1 antibody tests were examined through AIDS case surveilla

247 Of the 8155 at-risk individuals whose antibody tests were negative, 5 were HIV RNA positive.

248 HCV antibody tests were performed by the enzyme-linked immun

249 cts were interviewed and examined, and serum antibody tests were performed, along with blood cultures

250 es that yielded negative results on standard antibody tests were tested again with the use of nucleic

251 was the most potent antagonistic anti-IGF-IR antibody tested when compared with several commercially

252 s (HCV) RNA testing offers an advantage over antibody testing (which only indicates previous exposure

253 diagnostic limitations of direct fluorescent-antibody testing, which missed one-third of infected ind

254 IA offers increased sensitivity over current antibody tests while also allowing separate detection of

255 ization and normalization of solid phase HLA antibody tests will enable comparison of data across lab

256 as resistant to neutralization by all of the antibodies tested with the exception of the 2G12 antibod

257 e tested for influenza by direct fluorescent-antibody testing with PCR confirmation.

258 nimals did not react in indirect fluorescent-antibody tests with Babesia microti antigen, however, su

259 V antigen, the development of diagnostic HAV antibody tests with recombinant HAV antigen appears warr